Invasive cervical cancer is a leading cause of cancer death in women worldwide. miRNA may have roles in the pathogenesis of cervical cancer based on the increases or decreases in several specific miRNAs found in patients with this disease. The clinical outcomes of cervical cancer vary significantly and are difficult to predict. One unique challenge in cervical cancer biomarker study is the lack of large amounts of tumor tissues because most cervix biopsies are relatively small. The miRNA can affect HPV DNA replication shed more light on our understanding of the HPV life cycle and the mechanistic underpinnings of HPV induced oncogenesis. Also, miRNA processing proteins may be involved during early cervical cancer development. The E6 and E7 oncoproteins of HPV could induce the overexpression of DNA methyltransferase enzymes, which can catalyze the aberrant methylation of protein-coding and miRNA genes. Methods for diagnosis of cervical cancer include analysis of changes in the levels of specific miRNAs in serum and determination of aberrant hypermethylation of miRNAs. miRNAs are related on drug resistance and may be useful in combination therapy for cervical cancer with other drugs.

宫颈浸润癌是全球女性癌症死亡的主要原因。基于在患有这种疾病的患者中发现的几种特定miRNA的增加或减少，miRNA可能在子宫颈癌的发病机理中起作用。子宫颈癌的临床结果差异很大且难以预测。子宫颈癌生物标志物研究的一个独特挑战是缺乏肿瘤组织，因为大多数子宫颈活检组织都相对较小。miRNA可以影响HPV DNA复制为我们对HPV生命周期以及HPV诱导的肿瘤发生的机制基础提供了更多的了解。同样，miRNA加工蛋白可能参与子宫颈癌的早期发展。HPV的E6和E7癌蛋白可能会诱导DNA甲基转移酶的过表达，可以催化蛋白质编码和miRNA基因的异常甲基化。子宫颈癌的诊断方法包括分析血清中特定miRNA的水平变化以及确定miRNA异常甲基化。miRNA与耐药性有关，可能与其他药物一起用于宫颈癌的联合治疗。